Understanding the toxicities associated with antibody-drug conjugates could help oncologists develop strategies to diminish adverse events that arise during treatment with these powerful agents
Combining osimertinib with chemotherapy improved progression-free survival in EGFR-mutated non-small cell lung cancer, new interim data show, but experts have raised concerns about toxicity.
A new interim analysis finds more evidence that ibrutinib plus rituximab is a viable option for younger patients with untreated chronic lymphocytic leukemia compared with standard chemoimmunotherapy.
FDA OKs Trifluridine/Tipiracil Plus Bevacizumab for mCRC medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.